within Pharmacolibrary.Drugs.ATC.R;

model R05CA11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 0.2,
    adminDuration  = 600,
    adminMass      = 0.04,
    adminCount     = 1,
    Vd             = 0.14,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Levoverbenone is a monoterpene compound that has been included in antitussive (cough suppressant) products. It is the levorotatory isomer of verbenone and has been studied as an expectorant and mucolytic agent for the treatment of cough and respiratory conditions. It is not widely used or approved for clinical use in most countries today.</p><h4>Pharmacokinetics</h4><p>No primary pharmacokinetic publications found for levoverbenone in humans. All values below are estimated based on general characteristics of monoterpene-based expectorants administered orally to adults.</p><h4>References</h4><ol><li>Alexander N Shikov, Elena V Flisyuk, Ekaterina D Obluchinskaya, Olga N Pozharitskaya,Pharmacokinetics of Marine-Derived Drugs.,Marine drugs,2020<a href='https://pubmed.ncbi.nlm.nih.gov/33182407/'>https://pubmed.ncbi.nlm.nih.gov/33182407/</a></li><li>Hannah Katharine Batchelor, John Francis Marriott,Paediatric pharmacokinetics: key considerations.,British journal of clinical pharmacology,2015<a href='https://pubmed.ncbi.nlm.nih.gov/25855821/'>https://pubmed.ncbi.nlm.nih.gov/25855821/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R05CA11;
